Publications by authors named "S A al-Asady"
Article Synopsis
- A study examined late seizures (LS) after cerebral venous thrombosis (CVT) using data from 1,127 patients, focusing on their occurrence, characteristics, treatment, and predictors.
- About 11% of patients experienced LS during a median follow-up of 2 years, with the first seizure usually happening around 5 months post-CVT diagnosis.
- Key predictors for developing LS included having status epilepticus during the acute phase, undergoing decompressive hemicraniectomy, and experiencing acute seizures, highlighting a significant risk for recurrence which suggests the need for a proper epilepsy diagnosis.
Objective: To identify characteristics, predictors, and outcomes of acute symptomatic seizures (ASS) in cerebral venous thrombosis (CVT), we investigated 1,281 consecutive adult patients with CVT included from 12 hospitals within the International CVT Consortium.
Methods: We defined ASS as any seizure between symptom onset and 7 days after diagnosis of CVT. We stratified ASS into prediagnosis and solely postdiagnosis ASS.
1. The inhibition of lignocaine metabolism by beta-adrenoceptor antagonists (beta-blockers) was investigated in rat and human liver microsomes. 2.
View Article and Find Full Text PDFEffects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.
Br J Clin Pharmacol
September 1984
In theory, beta-adrenoceptor antagonists could lower the clearance of free lignocaine in three ways (a) by decreasing hepatic blood flow, (b) by competing for plasma binding sites or (c) by inhibiting the enzymes responsible for metabolising lignocaine. The first mechanism has been demonstrated for propranolol and is probably common to all agents lacking intrinsic sympathomimetic activity. The second mechanism is discounted by data showing that propranolol, one of the more highly bound beta-adrenoceptor antagonists, does not alter the free fraction of lignocaine in plasma.
View Article and Find Full Text PDF